S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$38.20
-0.95 (-2.43%)
(As of 09/29/2023 ET)
Compare
Today's Range
$38.16
$39.50
50-Day Range
$37.50
$44.03
52-Week Range
$29.85
$59.46
Volume
914,439 shs
Average Volume
885,290 shs
Market Capitalization
$5.04 billion
P/E Ratio
22.34
Dividend Yield
N/A
Price Target
$54.27

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
42.1% Upside
$54.27 Price Target
Short Interest
Bearish
5.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.92mentions of Halozyme Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.23 M Sold Last Quarter
Proj. Earnings Growth
44.35%
From $2.48 to $3.58 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.94 out of 5 stars

Medical Sector

38th out of 970 stocks

Biological Products, Except Diagnostic Industry

3rd out of 157 stocks


HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Price History

HALO Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
H.C. Wainwright Sticks to Their Buy Rating for Halozyme (HALO)
Expert Ratings for Halozyme Therapeutics
Goldman Sachs Sticks to Its Hold Rating for Halozyme (HALO)
Halozyme Therapeutics Q2 2023 Earnings Preview
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
8/08/2023
Today
9/30/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
393
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$54.27
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+42.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$202.13 million
Pretax Margin
37.47%

Debt

Sales & Book Value

Annual Sales
$660.12 million
Cash Flow
$2.53 per share
Book Value
$1.26 per share

Miscellaneous

Free Float
128,755,000
Market Cap
$5.04 billion
Optionable
Optionable
Beta
1.24

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 60)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.45M
  • Ms. Nicole  LaBrosseMs. Nicole LaBrosse (Age 40)
    Sr. VP & CFO
    Comp: $727.04k
  • Dr. Michael J. LaBarre Ph.D. (Age 59)
    Sr. VP & Chief Technical Officer
    Comp: $723.24k
  • Mr. Mark Snyder Esq.
    Chief Legal Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Dr. Christopher Bryant Ph.D. (Age 62)
    Chief Manufacturing Officer & Head of Technical Operations
  • Ms. Kristin Schwartzbauer
    Head of Quality
  • Mr. Gary Grote
    Chief Commercial Officer













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2023?

11 brokerages have issued 1 year price targets for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's share price to reach $54.27 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 at the beginning of the year. Since then, HALO stock has decreased by 32.9% and is now trading at $38.20.
View the best growth stocks for 2023 here
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.09. The biopharmaceutical company earned $221.04 million during the quarter, compared to analyst estimates of $201.91 million. Halozyme Therapeutics had a net margin of 30.21% and a trailing twelve-month return on equity of 254.75%.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $2.65-$2.75 for the period, compared to the consensus earnings per share estimate of $2.61. The company issued revenue guidance of $825.00 million-$845.00 million, compared to the consensus revenue estimate of $823.06 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $38.20.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.04 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 393 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -